
Home » Diabetomics’s Saliva-Based COVID-19 Test Gets FDA Emergency Use Authorization
Diabetomics’s Saliva-Based COVID-19 Test Gets FDA Emergency Use Authorization
The FDA has granted Diabetomics an Emergency Use Authorization for its COVID-19 antibody test, CovAb.
The test assesses saliva samples, delivers results within 15 minutes and detects all three COVID-19 antibody classes—IgA, IgG and IgM—that are present at different stages of infection.
The highly accurate test has 97.6 percent sensitivity and 98.8 percent specificity, according to the Hillsboro, Ore.-based company.
Upcoming Events
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar
-
08Mar